CNSY Cerenome Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CNSY

Price (delayed)

$1.95

Market cap

$14.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.36

Enterprise value

$12.48M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary ...

Highlights
The EPS has dropped by 135% since the previous quarter but it has surged by 93% year-on-year
CNSY's debt has dropped by 94% since the previous quarter but it is up by 47% year-on-year
Cerenome's net income has shrunk by 119% QoQ and by 37% YoY
CNSY's revenue is down by 21% YoY and by 19% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CNSY

CNSY stock price

How has the Cerenome stock price performed over time
Intraday
-3.94%
1 week
-4.41%
1 month
-36.48%
1 year
-80.69%
YTD
-84.78%
QTD
-55.38%

Financial performance

How have Cerenome's revenue and profit performed over time
Revenue
$4.2M
Gross profit
$4.2M
Operating income
-$26.4M
Net income
-$26.09M
Gross margin
100%
Net margin
-620.7%
CNSY's net margin has dropped by 170% since the previous quarter and by 73% year-on-year
CNSY's operating margin has dropped by 161% year-on-year and by 72% since the previous quarter
Cerenome's net income has shrunk by 119% QoQ and by 37% YoY
The operating income has plunged by 107% YoY and by 40% from the previous quarter

Price vs fundamentals

How does CNSY's price correlate with its fundamentals

Growth

What is Cerenome's growth rate over time

Valuation

What is Cerenome stock price valuation
P/E
N/A
P/B
2.46
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.97
The EPS has dropped by 135% since the previous quarter but it has surged by 93% year-on-year
The equity has surged by 80% year-on-year but it has dropped by 54% since the previous quarter
CNSY's P/B is 74% below its last 4 quarters average of 9.7
The P/S is 80% below the 5-year quarterly average of 16.8 and 61% below the last 4 quarters average of 8.5
CNSY's revenue is down by 21% YoY and by 19% QoQ

Efficiency

How efficient is Cerenome business performance
The return on sales has dropped by 166% since the previous quarter and by 115% year-on-year
The ROA has plunged by 107% from the previous quarter but it has grown by 28% YoY
The ROE has shrunk by 99% QoQ

Dividends

What is CNSY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CNSY.

Financial health

How did Cerenome financials performed over time
Cerenome's total assets is 64% higher than its total liabilities
The quick ratio has contracted by 42% from the previous quarter but it has grown by 12% YoY
Cerenome's current ratio has decreased by 40% from the previous quarter but it has increased by 9% YoY
CNSY's debt is 99% smaller than its equity
CNSY's debt has dropped by 94% since the previous quarter but it is up by 47% year-on-year
The debt to equity has dropped by 83% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.